Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@smh.ca.
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
|Sponsor Type||Funding Program Title||Amount and Duration||Description||Deadline|
|Tri-Agency||CIHR Team Grant: Diabetes Prevention and Treatment in Indigenous Communities: Resilience and Wellness||Letter of Intent stage: Development grants of up to $35,000 per grant.|
Full Application stage: Maximum $400,000 per year for up to 5 years, for a total of up to of $2,000,000 per grant.
|This supports Indigenous-led and community-driven research to define and integrate models of resilience and wellness into diabetes prevention and/or treatment approaches among First Nations, Inuit and Métis Peoples. This seeks applicants who are Indigenous community-based groups or non-governmental organizations, or individuals who self-identify as Indigenous (First Nations, Inuit or Métis) or provide evidence of having meaningful and culturally safe involvement with Indigenous Peoples.||Letter of Intent: May 26, 2021
Full Application: July 7, 2022
|Tri-Agency||CIHR Other: Hepatitis C Research||Up to $700,000 per year for up to 5 years for Research Area 1; up to $200,000 per year for up to 5 years for Research Area 2.||The Hepatitis C Research Initiative will primarily encourage a focus on hepatitis C prevention, testing and improved health outcomes for those living with hepatitis C; however, the successful applicants will be required to collaborate with other relevant research networks and teams. This opportunity will support a national collaborative research program relevant to the following two research areas: |
1 - Prevention of Hepatitis C and Reaching the Undiagnosed
2 - Long-Term Consequences and Cascade of Care
Webinar: CIHR plans to host webinar(s) to support participants with the requirements of the Hepatitis C Research opportunity. Links to follow at CIHR's Webinars page.
|June 1, 2021.|
|Tri-Agency||CIHR Team Grant: Indigenous Healthy Life Trajectories Initiative Cohort Research Study (I-HeLTI)||For the research grant, maximum $2,000,000 per year for up to 6 years. For the Collaborating Centre, maximum $350,000 per year for up to 6 years.||In 2019, three I-HeLTI research teams were funded to build the infrastructure and capacity needed to conduct an I-HeLTI Intervention Cohort Research Study. This funding opportunity will support the establishment of one I-HeLTI Intervention Cohort Research Study, as well as an I-HeLTI Collaborating Centre to support the activities of the cohort research study.|
NOTE: To be eligible, applicants must hold a Team Grant from the December 6, 2018, program launch of I-HeLTI where the funding start date of the grant was on November 1, 2019.
|June 9, 2021|
|Tri-Agency||CIHR Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C||Up to $100,000 per year for up to 1 year.||This funding opportunity will support projects across all pillars of research (biomedical research; clinical research; health services research; and social, cultural, environmental, and population health research) with a primary focus on STBBI of public health relevance including, but not limited to, chlamydia, gonorrhea, syphilis, hepatitis B and human papillomavirus (HPV). For any STBBI not listed above, applicants will be required to demonstrate the public health relevance of the disease-type being studied, and how it impacts the health of individuals nationally and globally.|
NOTE:Research projects focusing solely on HIV or hepatitis C will not be eligible for funding.
|June 9, 2021.|
|Tri-Agency||SSHRC Partnership Engage Grants||$7,000 to $25,000 for 1 year||Partnership Engage Grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. The small-scale, stakeholder-driven partnerships supported through the Partnership Engage Grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors.||June 15, September 15|
|Tri-Agency||CIHR Team Grant: Canadian Research Initiative on Substance Misuse (CRISM) Phase II: Regional Nodes||Regional Nodes: Up to $400,000 per year for up to 6 years; Controlled Trial: Up to $1,250,000 per year for up to 4 years.||This funding opportunity will support projects relevant to core infrastructure support for collaborative substance use research in the following 5 regions: British Columbia, Prairie, Ontario, Quebec, Atlantic Canada. This funding opportunity will also support one national controlled trial in the management of methamphetamine use disorder. This trial will be a collaborative project between the 5 Nodes.|
Applicants to this funding opportunity do not need to have previously received CRISM funding to be eligible.
|Letter of Intent: June 15, 2021.
Full Application and Controlled Trial Application (by invitation): January 6, 2022.
|Tri-Agency||CIHR Pre-announcement: Heart Failure Research Network Funding Opportunity||Up to $1,000,000 per year for up to 5 years.||This will support a single nationally coordinated, interdisciplinary heart failure research network to improve our understanding of the underlying causes, pathophysiology and social determinants of heart failure and to improve the prevention, detection, management, patient outcomes, quality of life, and delivery of care of this common and multifactorial condition.||Anticipated Deadlines:
Launch: Spring 2021
Registration: Summer 2021
Full Application: Winter 2021
|Tri-Agency||CIHR Team Grant: Indigenous Gender and Wellness Team Grant||Maximum $166,667 per year for up to 3 years, for a total of $500,000 per grant.||This will focus on addressing themes related to Indigenous gender and wellness. In this context, wellness should be broadly defined to encompass an Indigenous, holistic view of health. Projects can tie wellness to ceremony, language, culture, behaviours, land-based projects and more. Projects on topics important to Indigenous youth and young adults are especially encouraged.|
NOTE: Team Grants will not be restricted to those who received a Development Grant in Phase 2 of this initiative. However, at least one team member must have attended the Idea Fair and Learning Circle in June 2019.
|June 22, 2021.|
|Tri-Agency||NSERC Idea to Innovation Grants (I2I Grants)||Market Assessment: up to 12 months, $15,000; Phase I: up to 12 months, $125,000; Phase Ib: up to 6 months, $60,000; Phase IIa: from 6 to 18 months, $125,000; Phase IIb: up to 24 months, $350,000||The objective of the Idea to Innovation (I2I) grants is to accelerate the pre-competitive development of promising technology originating from the university and college sector and promote its transfer to a new or established Canadian company.||June 28, 2021; September 27, 2021.|
|Tri-Agency||NSERC Alliance/Mitacs Accelerate Grants||--||This is for applicants seeking support from both an Alliance grant and Mitacs Accelerate, to apply through a single application submission and review process. Applicants who wish to include Mitacs Accelerate internships in their Alliance application should contact their local Mitacs business development representative to obtain the NSERC/Mitacs joint application form.||Ongoing|
|Tri-Agency||NSERC Alliance Grants||$20,000 to $1 million per year for 1-5 years||Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors.|
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
|Other Canadian||Canadian Foundation for Pharmacy (CFP) Innovation Fund Grant||Not specified. Up to $150,000 will be available.||This supports a pharmacist engaged in research or an innovative model of pharmacy practice that seeks to advance the profession in ways that can demonstrably improve the health of patients.||Letter of Intent: May 7, 2021.
Application (by invitation): TBA. Expected at end of July, 2021.
|Other Canadian||Call for Applications: New Digital Research Infrastructure Organization (NDRIO)-Portage COVID-19 Data Curation Funding||Up to $42,000.||The purpose of this funding is to bring COVID-19 related data into timely compliance with the FAIR Guiding Principles for the management of research data, algorithms, tools and workflows. This funding may only be used for the contracting of HQP for the stewardship or curation of data from research related to the COVID-19 pandemic.||Deadline: May 21, 2021.|
|Other Canadian||Brain Canada-Quebec Consortium for Drug Discovery (CQDM) Quantum Leap Program||$500,000 to $1,200,000.||This program aims to support innovative translational biopharmaceutical research projects that have the potential to improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs. Brain Canada is partnering with the Quantum Leap pharma-led funding program for drug discovery research on eligible brain related projects.||Deadline: May 26, 2021.
Information Session: April 28, 12PM-1PM EST. Please register here: link.
|Other Canadian||Canadian Allergy, Asthma, and Immunology Foundation (CAAIF): Various Opportunities||CAAIF-Miravo Healthcare Research Grant in Allergic Rhinitis or Urticaria: $25,000 for 1 year.|
CAAIF Top 10 Challenge Food Allergy Research Grant: $25,000 for 1 year.
|CAAIF-Miravo Healthcare Research Grant in Allergic Rhinitis or Urticaria : The project should be focused on allergic rhinitis or urticaria (including but not limited to its development, persistence, desensitization, remission, diagnosis, clinical manifestation). |
CAAIF Top 10 Challenge Food Allergy Research Grant: This funds a patient-oriented food allergy research grant.
|May 31, 2021.|
|Other Canadian||Workplace Safety and Insurance Board (WSIB) 2021 Grants Program Strategic Initiative: Occupational Asbestos Exposure and Development of Gastro-intestinal Cancers (Systematic Review)||--||WSIB seeks to fund one new award for a systematic review of the scientific evidence examining if occupational asbestos exposure causes gastro-intestinal cancers. To express interest and obtain an application form, please email firstname.lastname@example.org.||May 31, 2021.|
|Other Canadian||Grand Challenges Canada: Stars in Global Health||Up to $100,000 for up to 12 months.||This seeks bold ideas that will improve the sexual and reproductive health and rights of women, adolescents, children and LGBTQI+ people in Sub-Saharan Africa. The bold ideas are expected to improve the access, use and quality of comprehensive sexual and reproductive health education and services and to be resilient to pandemic control measures like those introduced to control COVID-19. Of particular interest to Grand Challenges Canada are innovations that improve responses to sexual- and gender-based violence.||Deadline: June 3, 2021.|
|Other Canadian||Mitacs Globalink Research Internship (GIS): Summer of 2022 Call for Applications||--||GRI is now accepting faculty project submissions for Summer 2022. GRI pairs faculty in Canada with international undergrads for 12-week research projects from May to October.||Deadline: June 9, 2021.|
|Other Canadian||Trans-Atlantic Platform (T-AP) for Social Sciences and Humanities Recovery, Renewal and Resilience in a Post-Pandemic World (RRR) Call for Proposals||Between $150,000-$200,000 for 2-3 years.||This emphasizes the following five main challenges related to COVID-19: (i) reducing inequalities and vulnerabilities; (ii) building a more resilient, inclusive and sustainable society; (iii) fostering democratic governance and political participation; (iv) advancing responsible and inclusive digital innovation; and (v) ensuring effective and accurate communication and media.||Intent to Submit: June 14, 2021.
Full Proposal: July 12, 2021.
|Other Canadian||U of T Temerty Knowledge Translation Grant: Addressing health inequities in disadvantaged populations||Up to $100,000 for 1 year.||These are designed to fund collaborative research projects by faculty members in Temerty Medicine working with community organizations to address health inequities in our disadvantaged populations.||June 15, 2021.|
|Other Canadian||Brain Tumour Foundation of Canada (BTFC) Research Grants||Up to $25,000 for up to 2 years.||BTFC seeks outstanding researchers conducting quality brain tumour research. All such proposals will be given consideration. Additionally, we are interested in receiving innovative research proposals which incorporate novel or original concepts that have the potential to make a difference and projects that involve collaboration. Adult and pediatric brain tumour projects in basic, clinical or translational research will be considered.||June 18, 2021.|
|Other Canadian||Banting Postdoctoral Fellowships Program (2021-2022)||Up to $70,000 per year for up to 2 years.||This is a very competitive award, with 70 fellowships awarded each year across Canada. Each institution can only put forward their top-tier candidates, defined as the top 20% of all postdocs. Unity Health Toronto will hold an internal competition to select applicants. We have sent the research community an email regarding this process. If you did not receive this and are interested in applying, email Arianna.Rath@unityhealth.to ASAP so we can forward the application materials and internal deadlines.||Internal Notice of Intent: June 30, 2021.
Sponsor Deadline: September 22, 2021.
|Other Canadian||Pre-Announcement: New Digital Research Infrastructure Organization (NDRIO) Inaugural Funding Opportunity (IFO)||Funding Stream 1: $100,000 to $1M; Funding Stream 2: $1M to $3M.||The IFO aims to build national research capacity and deliver on NDRIO's mandate to create a broad and integrated Canadian digital research infrastructure (DRI) ecosystem. Specifically, the IFO will address the needs of the research community related to DRI, while promoting an equitable and inclusive DRI environment in Canada. The IFO will be open to proposals from all research disciplines, and with strong encouragement for inter-provincial collaborations and multi-disciplinary partnerships.||Tentative Deadlines: To be confirmed when competition opens on May 1, 2021.
Letter of Intent: Opens May, 2021. Reviewed and selected July-August, 2021.
Full Proposal (by invitation): Opens September, 2021. Adjudicated January-March, 2022.
If you are interested in applying for this opportunity, please let us know by email to VPRI@smh.ca.
|Other Canadian||Ontario Early Researcher Awards (ERA) Program - Round 16||--||The ERA Program funds full-time new researchers to build a research team. The submission must go through the institute, and has an internal peer review process and internal timelines.||If you are interested in applying, email VPRI@smh.ca. ASAP so we can forward the application materials and internal deadlines.|
|Other Canadian||Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs||--||The NRC offers potential opportunities for collaboration in the following areas:|
- Aging in Place
- Artificial Intelligence for Design
- Disruptive Technology Solutions for Cell and Gene Therapy
- High-throughput and Secure Networks
- Pandemic Response
Potential collaborators can register their interest to work with NRC on the Challenge Programs website.
|Other Canadian||Government of Canada: CanExport for Innovators||Maximum of $75,000||Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.|
Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities.
|Other Canadian||Weston Brain Institute: Early Phase Clinical Trials: Canada||Up to $1,500,000 per project for up to 4 years||Funding for clinical trials and/or clinical trial sub-studies with excellent preliminary data.||Rolling deadline
|Other Canadian||Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant||Health Research Grant: Up to $250,000 for 3 years.|
New Investigator Grant: Up to $300,000 for 3 years.
|Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment.||Rolling deadline|
|Other Canadian||Telus Funds||Various||For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition.||Various
|Other Canadian||Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program||Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.)||This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).|
If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to).
|Other Canadian||Mitacs Accelerate Graduate Student Internships||$15,000 award (with at least $10,000 to support the student stipend and the balance available for project resources)||The Mitacs Accelerate program helps fund partnered research projects by supporting Masters, PhD students, or postdoctoral fellows through "units" consisting of 4-month paid graduate student internships.||No Deadline|
|International||American Academy of Pediatrics (AAP) Neonatal Resuscitation Program (NRP) 2021 Grants||NRP Human Factors or Education Grant: Up to USD $15,000 for 1 year.|
NRP Young Investigator Award:Up to USD $15,000 for 1 year.
NRP Research Grant Program: Up to USD $50,000 for 1 year.
|NRP Human Factors or Education Grant: Any health care professional with an interest in human factors impact on delivery room resuscitation or optimization of NRP education.|
NRP Young Investigator Award:Physicians-in-training or individuals within four years of completing fellowship training.
NRP Research Grant Program: Any health care professional with an interest in Neonatal Resuscitation.
|Intent to Apply: May 7, 2021.
Full Application (by invitation): August 20, 2021.
|International||Pfizer Global Medical Grants (GMG) and Rethink Request for Proposal (RFP): Quality Improvement Initiative in Metastatic Breast Cancer||Up to CAD $100,000 for ~2 years.||This encourages proposals for the implementation of strategies that will measurably improve the quality of care of metastatic breast cancer (mBC) patients. Projects should use optimal measures to improve |
care for patients with metastatic breast cancer, where treatment goals focus on improving quality and length of life.
|May 13, 2021.|
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY21 Peer Reviewed Medical Research Program (PRMRP)||Clinical Trial Award: 1) Clinical trial only: funding limit not defined; up to 4 years; 2) Planning Phase with clinical trial: Up to USD $500,000 for the planning phase and up to 18 months for the planning phase.|
Focused Program Award: Up to USD $7.2 million for up to 4 years.
|Applications must address one or more of the potential FY21 PRMRP Topic Areas listed in the funding opportunities:|
- Clinical Trial Award: 1) Clinical trial only 2) Planning Phase with clinical trial
- Focused Program Award
|Clinical Trial Award:
Deadlines: Pre-Application- May 13, 2021. Application- August 26, 2021.
Focused Program Award:
Deadlines: Pre-Application- May 13, 2021. Application- August 26, 2021.
|International||Biogen: Various Opportunities||--||Biogen considers requests across a variety of disease areas including Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Biosimilars (Crohn's Disease and Rheumatoid Arthritis), Multiple Sclerosis, and Spinal Muscular Atrophy. The Biogen website lists the specific areas of interest for each opportunity below:|
- Medical Education: Supports independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.
- Patient Education: Supports independent educational activities for patients or caregivers.
- General Grant: Supports a project or program that does not fit any of the other defined grant categories.
|May 15, August 15, November 1.|
|International||United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP) FY 2021 Spinal Cord Injury Research Program (SCIRP): Various Opportunities||Clinical Trial Award: Up to USD $3M for up to 4 years.|
Translational Research Award: Up to USD $1.25M for up to 3 years.
Investigator-Initiated Research Award: Up to USD $500,000 for up to 3 years.
|Clinical Trial Award: Funds Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of SCI and its consequences. |
Translational Research Award: Funds studies that accelerate the movement of promising ideas in SCI research into clinical applications.
Investigator-Initiated Research Award: Funds SCI-related research that has the potential to make an important contribution to SCI research, patient care, and/or quality of life. Studies focused exclusively on target identification are discouraged.
Pre-application: May 24, 2021.
Application (by invitation): September 3, 2021.
|International||United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP) FY21 Peer Reviewed Orthopaedic Research Program (PRORP): Various Opportunities||Applied Research Award: Up to USD $725,000 for up to 3 years.|
Clinical Trial Award: Level 1: Up to USD $2.25M for up to 4 years; Level 2: Up to USD $2.75M for up to 4 years.
Clinical Translational Research Award: Up to USD $1.5M for up to 4 years.
|Applied Research Award: Supports research applications focused on advancing optimal treatment and restoration of function for individuals with musculoskeletal injuries. Clinical research and clinical trials are not allowed. |
Clinical Trial Award: Supports rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat-related orthopaedic injuries or non-battle injuries.
Clinical Translational Research Award: Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial. Funding must support clinical research studies involving humans.
Pre-application: May 27, 2021.
Application (by invitation): September 10, 2021.
|International||Coalition for Epidemic Preparedness Innovations (CEPI) Calls for Proposals||Complementary clinical trials: Expanding access to COVID-19 vaccines and rapid response to clinical development gaps: Up to USD $140 million.||Complementary clinical trials: Expanding access to COVID-19 vaccines and rapid response to clinical development gaps: This is to rapidly expand access to and confidence in COVID-19 vaccines by i) generating clinical evidence in special / sub-populations / age groups or ii) addressing clinical development gaps. Clinical trials which expand access and capacity in low- and middle-income countries (LMICs) are particularly encouraged.||Complementary clinical trials: Expanding access to COVID-19 vaccines and rapid response to clinical development gaps: Expressions of Interest accepted on a rolling basis until May 28, 2021.
|International||Society of Interventional Radiology (SIR) Foundation: Various Opportunities||Funding Source Development Grant : Up to USD $25,000 for up to 1 year.|
Academic Transition Grant : Up to USD $25,000 for up to 1 year.
Pilot Research Grant Program : Up to USD $25,000 for up to 1 year.
|Funding Source Development Grant : This supports projects in clinical research areas important to the advancement of interventional radiology and patient care that align with SIR Foundation's clinical research goals. |
Academic Transition Grant : Designed for interventional radiologists over the age of 40 who have recently begun academic careers after spending several years in non-academic practice.
Pilot Research Grant Program : Funds research in areas identified by SIR Foundation as important to the advancement of interventional radiology and patient care.
|Funding Source Development Grant : Letter of Intent: May 28, 2021; Application: December 14, 2021.
Academic Transition Grant : Proposal Development Form: June 30, 2021; Application: January 15, 2022.
Pilot Research Grant Program : Proposal Development Form: June 30, 2021; Pre-Review: October 15, 2021; Application: January 15, 2022.
|International||Alzheimer's Drug Discovery Foundation (ADDF): Core Funding Programs||Up to USD $600,000 or $3,000,000.||Drug Development: This supports in vivo preclinical studies that advance lead molecules developed for Alzheimer's disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.|
Value: Up to USD $600,000 for 1 year.
Program to Accelerate Clinical Trials (PACT): This supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. Value: Up to USD $3,000,000 for multi-year projects.
Neuroimaging and CSF Biomarker: This aims to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.
Value: Up to USD $600,000 for 1 year.
Prevention Pipeline: This supports studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
Value: Up to USD $3,000,000 for multi-year projects.
NOTE: Amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for the Drug Development or PACT RFPs.
|Letter of Intent: May 28, 2021; October 1, 2021.
Invited Full Proposal: April 16, 2021; July 30, 2021; December 3, 2021.
|International||The U.S. Agency for International Development (USAID) Global Health Broad Agency Announcement for Research and Development||Various||This Broad Agency Announcement (BAA) seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health.||May 30, 2022|
|International||Craig H. Neilsen Foundation: Various Opportunities||Spinal Cord Injury Research on the Translational Spectrum:|
Pilot Research Grants: Up to USD $150,000 per year for 2 years;
Senior Research Grants: Up to USD $200,000 per year for 3 years.
Spinal Cord Injury Research on the Translational Spectrum: This supports research to improve the understanding of traumatic spinal cord injury and develop new approaches to alleviate the dysfunction and complications that follow. The scope of this portfolio is broad, encompassing mechanistic, preclinical modeling, translational and/or clinical research.
Spinal Cord Injury Research on the Translational Spectrum:
Letter of Intent: June 11, 2021
Full Grant Application (by invitation): November 16, 2021
|International||United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP) FY 2021 Peer Reviewed Alzheimer's Research Program (PRARP): Various Opportunities||Convergence Science Research Award: Funding Level 1: Up to USD $225,000; Funding Level II: Up to USD $500,000. Up to 3 years for both funding levels.|
Innovation in Care and Support Award: Funding Level 1: Up to USD $225,000; Funding Level II: Up to USD $500,000. Up to 3 years for both funding levels.
Research Partnership Award: Up to USD $1.3M for up to 3 years.
Accelerating Diagnostics Research Award: Up to USD $2.8M for up to 4 years.
Leveraging Approaches for Innovation in Care and Support Award: Up to USD $2.8M for up to 4 years.
|Convergence Science Research Award: Supports innovative and impactful efforts to generate research resources, tools, and new avenues of investigation for researchers and practitioners in the health sciences. Value: Funding Level 1: Up to USD $225,000; Funding Level II: Up to USD $500,000. Up to 3 years for both funding levels.|
Innovation in Care and Support Award: Supports innovative and impactful research that improves the quality of life and care for individuals, families, and care providers living with AD/ADRD. Value: Funding Level 1: Up to USD $225,000; Funding Level II: Up to USD $500,000. Up to 3 years for both funding levels.
Research Partnership Award: Supports collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. Value: Up to USD $1.3M for up to 3 years.
Accelerating Diagnostics Research Award: Supports high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD. Value: Up to USD $2.8M for up to 4 years.
Leveraging Approaches for Innovation in Care and Support Award: Supports innovative and impactful research that improves the quality of life and care for individuals, families, and care providers living with AD/ADRD. Value: Up to USD $2.8M for up to 4 years.
|Pre-Application: June 14, 2021.
Application: July 21, 2021.
|International||ResMed Foundation: Physician and Public Awareness||USD $10,000.||This is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public. Only programs that have wide outreach to a significant clinical or public population base will be considered.||June 15, 2021; December 15, 2021.|
|International||Mendez National Institute of Transplantation Foundation (MNITF) Research Grant Program (RGP)||USD $50,000 - $100,000 for 1 year.||These grants support innovative research to advance the science and practice of organ transplantation. Research in the following areas is considered: clinical outcomes in transplantation; donor screening technologies, immunogenetics, post-transplant monitoring, and advancements in regenerative medicine; new diagnostic and therapeutic paradigms; empowering patients with end-stage organ disease and transplant recipients through education to proactively manage their health and improve their long-term outcomes.||Letter of Intent: June 15, 2021; November 1, 2021.
Application (by invitation): July 31, 2021; December 15, 2021.
|International||ResMed Foundation Grants||Physician and Public Awareness Proposals: USD $10,000.|
Clinical Research Proposals: USD $250,000.
| Physician and Public Awareness Proposals: To further the awareness and knowledge of the inherent dangers of untreated SDB, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.|
Clinical Research Proposals: The Foundation will consider proposals focused on the evaluation, diagnosis, treatment and management of sleep disordered breathing (SDB) and other respiratory disorders. Research areas of interest are also other morbidities that are associated with SDB which include cardiovascular disease, metabolic syndrome, diabetes and morbid obesity. The Foundation is also interested in the application of novel screening and diagnostic tools to identify more easily SDB/OSA, as well as new and better paradigms to improve patient adherence and compliance with positive airway pressure and ventilation-based treatment methods.
|Physician and Public Awareness Proposals: June 15 and December 15, 2021.
Clinical Research Proposals: September 15, 2021.
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY21 Kidney Cancer Research Program (KCRP): Various Opportunities||Idea Development Award: USD $600,000, $650,000 or $2,000,000 for 3 or 4 years.|
Translational Research Partnership Award: Up to USD $750,000 for up to 3 years.
- Idea Development Award: Support innovative ideas and high-impact approaches, based on scientifically sound evidence, to move toward the KCRP vision of eliminating kidney cancer.
- Translational Research Partnership Award: Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications.
|Concept Award: Pre-Application: June 22, 2021; Application: July 13, 2021.
Idea Development Award: Pre-Application: June 15, 2021; Application (by invitation): October 5, 2021.
Translational Research Partnership Award: Pre-Application: June 15, 2021; Application (by invitation): October 5, 2021.
|International||Pfizer Global Medical Grants (GMG): Pfizer and Lilly Request for Proposals (RFP) Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain||Up to USD $200,000.||This support virtual and potentially live programs and other innovative digital medical education for HCPs. The focus is on Osteoarthritis (OA) and Chronic Pain associated with OA and patient-centered standard of care and management including pain and function, the biopsychosocial aspects of the disease, the complexities and challenges of care, and the future of OA/OA pain management. Programs targeted towards reviewing data at virtual or live osteoarthritis, rheumatology, pain, primary care, or other associated medical conferences, including but not limited to OARSI, EULAR, PAINWeek, AAFP, WCO, and ACR are of particular interest, as well as other meaningful education outside of congresses.||The RFP will open while funds last. Review deadlines for 2021 are June 18, 2021 and August 20, 2021.|
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY21 Breast Cancer Research Program (BCRP): Various Opportunities||Breakthrough Award Levels 1 and 2: Level 1 Value: Up to USD $450,000 or up to USD $750,000 (Partnering PI) for up to 3 years. Level 2 Value: Up to USD $1M or $1.5M or up to USD 1.5M or $2.0M (Partnering PI) for up to 4 years. |
Breakthrough Award Level 3:Up to USD $4M or USD $5M (Partnering PI) for up to 4 years.
Breakthrough Award Level 4:Up to USD $10 for up to 4 years.
Era of Hope Scholar Award: Up to USD $3M for up to 4 years.
Innovator Award: Up to USD $7M for up to 4 years.
Transformative Breast Cancer Consortium Award:Up to $25M for up to 4 years.
|Breakthrough Award Levels 1 and 2: Supports promising research that has high potential to lead to or make breakthroughs in breast cancer. |
Breakthrough Award Level 3: Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
Breakthrough Award Level 4: Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
Era of Hope Scholar Award: Supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer.
Innovator Award: Supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer.
Transformative Breast Cancer Consortium Award: Support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer.
|Breakthrough Award Levels 1 and 2: Pre-Application: August 31, 2021; Application: September 14, 2021.
Breakthrough Award Level 3: Pre-Application: June 24, 2021; Invited Application: October 5, 2021.
Breakthrough Award Level 4: Pre-Application: June 24, 2021; Invited Application: October 5, 2021.
Era of Hope Scholar Award: Pre-Application: August 31, 2021; Application: September 14, 2021.
Innovator Award: Pre-Application: June 24, 2021; Application: October 5, 2021.
Transformative Breast Cancer Consortium Award: Pre-Application: June 24, 2021; Invited Application: October 5, 2021.
|International||Society of Interventional Radiology (SIR) Foundation Dr. Ernest J. Ring Academic Development Grant||Up to USD $50,000 for 2 years.||This funding mechanism is intended for junior Interventional Radiology (IR) faculty with dedicated research time. Applications should propose research that will advance the science of IR. Applicants must be within the first five years of their initial faculty appointment after having completed all formal training. Only applicants holding a position up to and including the assistant professor level at the time of application are eligible. NOTE: Only one application may be submitted in a given year from each institution.||Development Form: June 30, 2021.
Application: January 15, 2022.
|International||Paralyzed Veterans of America (PVA) Research Foundation: Various Opportunities||Up to USD $75,000 for 1 year or up to $150,000 for 2 years.|| Basic Science: Laboratory research in the basic sciences to find a cure for SCI/D.|
Clinical: Clinical and functional studies of the medical, psychosocial and economic effects of SCI/D, and interventions to alleviate these effects.
Design and Development: Of assistive technology for people with SCI/D, which includes improving the identification, selection and utilization of these devices
|July 1, 2021.|
|International||Sigma Theta Tau International Honor Society of Nursing (STTI): Various Opportunities||Sigma/Doris Bloch Research Award: Up to USD $5,000 for up to 1 year|
Sigma/Joan K. Stout, RN, Research Grant: Up to USD $5,000
Sigma/American Nurses Credentialing Center Evidence-Based Practice Implementation Grant: Up to USD $20,000
|Sigma/Doris Bloch Research Award: This encourages nurses to contribute to the advancement of nursing through research. |
Sigma/Joan K. Stout, RN, Research Grant: This is to advance ongoing evidence-based study by nurse researchers on the impact of the practice of simulation education in schools of nursing and clinical care settings.
Sigma/American Nurses Credentialing Center Evidence-Based Practice Implementation Grant: This encourages nurses in clinical settings to apply evidence to practice and evaluate the effects on patient outcomes.
|Sigma/Doris Bloch Research Award: July 1, 2021.
Sigma/Joan K. Stout, RN, Research Grant: July 1, 2021.
Sigma/American Nurses Credentialing Center Evidence-Based Practice Implementation Grant: July 1, 2021.
|International||Glaucoma Research Foundation (GRF): Shaffer Fund for Innovative Glaucoma Research||Up to USD $50,000 for 1 year.||This supports new high-impact clinical, epidemiological and laboratory research based on GRF's strategic research goals: Protect and restore the optic nerve; Accurately detect glaucoma and monitor its progress; Find the genes responsible for glaucoma; Understand the intraocular pressure system and develop better treatments; Determine the risk factors for glaucoma damage using systematic outcomes data.||Preliminary Proposal: July 15, 2021.
Application: September 30, 2021.
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY21 Peer Reviewed Cancer Research Program (PRCRP): Various Opportunities||Behavioral Health Science Award: Up to USD $1 million for up to 4 years.|
Career Development Award - Fellow Option: Up to USD $400,000 for up to 3 years.
Idea Award: Up to USD $500,000 for up to 3 years.
Impact Award: Up to USD $1.25 million for up to 3 years.
Translational Team Science Award: Up to USD $2.5 million for up to 4 years. Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
|Applications must address one or more of the FY21 PRCRP Topic Areas listed in the funding opportunities. Research applications in the areas of breast, kidney, lung, pancreatic, prostate, ovarian, rare cancer, or melanoma are prohibited are prohibited and will not be accepted.|
Behavioral Health Science Award: Preliminary data are required, pilot clinical trials are allowed. Up to USD $1 million for up to 4 years. Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
Career Development Award - Fellow Option: PI must be at or above the level of Assistant Professor (or equivalent) and within 7 years after completion of their terminal degree. Preliminary data are not required, clinical trials are not allowed. Up to USD $400,000 for up to 3 years. Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
Idea Award: Preliminary data are not required, clinical trials are not allowed. Application submission is by invitation only. Up to USD $500,000 for up to 3 years. Deadlines: Pre-Application- May 20, 2021. Application- September 8, 2021.
Impact Award: Preliminary data are required, clinical trials are allowed. Application submission is by invitation only. Up to USD $1.25 million for up to 3 years. Deadlines: Pre-Application- May 20, 2021. Application- September 8, 2021.
Translational Team Science Award: Preliminary data are required, clinical trials are allowed. Up to USD $2.5 million for up to 4 years. Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
|Behavioral Health Science Award: Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
Career Development Award - Fellow Option: Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
Idea Award: Deadlines: Pre-Application- May 20, 2021. Application- September 8, 2021.
Impact Award: Deadlines: Pre-Application- May 20, 2021. Application- September 8, 2021.
Translational Team Science Award: Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
|International||Merck 2021 Research Grants||40,000 € - 450,000 € per year for up to 3 years.||Merck is offering a series of research grants to stimulate innovative research in: Drug Discovery; Real time testing and sensors; Nanoparticles for nucleic acid delivery; Digital Innovation; Biooelectronics; Sustainability; Media recycling for cultured meat; Organoids.||August 31, 2021.|
|International||Bristol-Myers Squibb/Pfizer Alliance Education Request for Proposals (RFP) in Atrial Fibrillation (AF) and Venous Thromboembolism (VTE)||Up to USD $150,000.||Grant proposals can address either AF or VTE or both areas. Projects that will be considered for support will focus on improving the care of patients by addressing knowledge gaps in the areas listed on the RFP website, including, but not limited to: updates on anticoagulation guidelines/guidance, anticoagulation in special populations, bleeding and thrombosis risk assessment through patient characteristics.||Accepted on a rolling basis until September 1, 2021. This RFP will remain open while funds last.|
|International||Laerdal Foundation for Acute Medicine||NOK 250,000 (USD ~$30,000) for 1 year.||The Laerdal Foundation focuses on practically oriented research. "The Chain of Survival" and "The Utstein Formula for Survival" have been established as metaphors for understanding system factors that impact the chances of survival. The Foundation Board wishes to contribute to a continued documentation and validation on how these concepts may reflect current medical, educational and implementation science. There, in particular, is a need for improved understanding of factors contributing to educational efficiency and the process of implementing scientific evidence into practice.||October 1, 2021.|
|International||Morton Cure Paralysis Fund (MCPF) Research Grant||USD $5,000 to $75,000 for 1 year.||This funds activities that hold promise of identifying therapies (cures) for paralysis in humans. MCPF has particular focus of enabling scientists to develop the proof concept data necessary to apply for larger grants. The focus areas are: |
1. Understanding the effects of spinal cord injury at the cellular level, particularly with emphasis on that which determines apoptosis and/or prohibits regrowth.
2. Studying strategies to promote neuronal growth and survival, encourage the formation of synapses, enhance the production of myelin, restore conduction capabilities, or otherwise lead to restoration of the compromised circuitry in the acutely and chronically injured CNS.
3. Evaluating new therapies in clinical trial.
|October 31, 2021.|
|International||Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) Multiple Sclerosis Research Program (MSRP)||Clinical Trial Award: Funding Level 1) Early-phase, proof-of-principle clinical trials. Up to USD $1M for up to 3 years. Funding Level 2) Larger scale clinical trials at phase 1 or 2 to determine efficacy. Up to USD $3M for up to 4 years.|
Early Investigator Research Award: Up to USD $200,000 for up to 2 years.
Exploration - Hypothesis Development Award: Up to USD $150,000 for up to 2 years.
|The CDMRP has pre-announced the following FY 2021 opportunities. Please see details of these at the MSRP link.|
-Clinical Trial Award
-Early Investigator Research Award
-Exploration - Hypothesis Development Award
-Investigator-Initiated Research Award:
|International||Pre-Announcements: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): Various Programs||--||Chronic Pain Management Research Program|
- Investigator-Initiated Research Award
- Translation Research Award
- Clinical Exploration Award
|International||Pfizer Global Medical Grants (GMG): COVID-19 Vaccine Grants||--||COVID-19 Vaccine General Research (now open): Pfizer is accepting COVID-19 general research grant requests that address the following areas: Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations.|
- Epidemiology studies evaluating direct & indirect impact, including modeling approaches, of Pfizer's vaccine particularly in specific patient populations.
- Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake.
COVID-19 Vaccine Independent Medical Education (coming soon): Optimize the prevention of COVID-19 by:
- Increase awareness of the risk of COVID-19 for all ages and racial and ethnic groups.
- Increase the understanding, and familiarity with, the proper storage, handling and administration of Pfizer's vaccine.
|Vaccine General Research: Rolling submission.
Independent Medical Education: TBA
|International||Alzheimer's Association: International Research Grant Program||--||Multiple Opportunities||Various
|International||Solving Kids Cancer (SKC): Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research.||$50,000 to $500,000 USD for up to 2 years.||The TDI of SKC only supports clinical research.||Preliminary Proposal Deadline: Ongoing|
|NIH||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Research Project Grant (R01 - Clinical Trial Required)||--||This supports research in areas relevant to normal and abnormal human development, including: contraception, fertilization, pregnancy, childbirth, prenatal and postnatal development; childhood development through adolescence; intellectual and developmental disabilities; and rehabilitation medicine. This is specifically for applications that propose one or more clinical trials.||May 7, 2021 (for AIDS and AIDS-related applications)|
|NIH||NIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health||--||This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels.||This notice applies to due dates on or after May 7, 2021, and subsequent receipt dates through June 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning||--||This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI.||This notice applies to due dates on or after May 7, 2021 and subsequent receipt dates through September 7, 2024.|
|NIH||NIH Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity: Various Opportunities||--||The purpose of these Funding Opportunity Announcements (FOAs) is to lay the groundwork for developing interventions at the network/circuit level that might be used as potential treatments for cognitive, affective, or social deficits in psychiatric disorders. These FOAs support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing.|
PAR-21-175 (R01 Clinical Trial Optional)
PAR-21-176 (R21 Clinical Trial Optional)
|Standard dates apply until May 8, 2024.|
|NIH||Neural Regulation of Cancer|
- PAR-19-353 (R01 Clinical Trial Not Allowed)
- PAR-19-354 (R21 Clinical Trial Not Allowed)
|--||These opportunities encourage collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer.||May 27, 2021; October 21, 2021; May 27, 2022|
|NIH||NIH Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)||--||This supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Applications are sought for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications).||June 2, 2021.|
|NIH||NIH Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children||--||This highlights interest in research to understand the mental health impact of the COVID-19 pandemic on school-aged children, specifically ages 3 - 12. Particularly, NIH is interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children.||This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through September 8, 2022.|
|NIH||NIH Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)||--||This supports studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.||This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through January 7, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration||--||The specific research objectives of this NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer's disease (AD) and AD-related dementias (ADRD).||This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through May 7, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers||--||This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.||This notice applies to due dates on or after June 5, 2021, and subsequent receipt dates through January 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Telehealth in Cancer Care||--||This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged.||This notice applies to due dates on or after June 5, 2021, and subsequent receipt dates through March 8, 2024.|
|NIH||Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)||--||This invites exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.||June 8, 2021; November 17, 2021|
|NIH||Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)||--||This invites Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. A Cooperative Agreement means that after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.||June 8, 2021; November 17, 2021|
|NIH||Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)||--||This invites Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. A Cooperative Agreement means that after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.||June 8, 2021; November 17, 2021|
|NIH||Single-Site Investigator-Initiated Clinical Trials (R61/R33)||--||This grant supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||June 10, 2021; October 14, 2021; February 11, 2022; June 10, 2022|
|NIH||Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)||--||This grant supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||June 10, 2021; October 14, 2021; February 11, 2022; June 10, 2022|
|NIH||NIH National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunity Announcements (FOAs): Various Opportunities||--||NIMH solicits clinical trial applications through a series of FOAs that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials.|
PAR-21-129: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)
PAR-21-130: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
PAR-21-131: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)
PAR-21-132: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
|June 15, 2021; October 15, 2021; February 15, 2022; June 15, 2022; October 14, 2022; February 15, 2023; June 15, 2023; October 17, 2023; February 15, 2024.|
|NIH||NIH Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)||--||This encourages theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. Other outcomes of interest include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.||June 16, 2021; October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; October 16, 2023.|
|NIH||National Cancer Institute (NCI) Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)||--||This grant supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities.||June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022|
|NIH||NIH HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards. The limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application.||June 22, 2021, October 13, 2021, June 9, 2022, October 11, 2022, June 9, 2023, and October 10, 2023.|
|NIH||NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic / pharmacodynamic (PK/PD) studies are also responsive. This FOA is not specific for any one or group of pain conditions.||June 22, 2021, October 13, 2021, June 9, 2022, October 11, 2022, June 9, 2023, and October 10, 2023.|
|NIH||NIH Triadic Interactions in Clinical Encounters Involving People with Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional)||--||This solicits basic research and Stage I behavioral intervention development clinical trials in two high-priority areas: (1) triadic communication and interpersonal relationships between patients, clinicians, and care partners; and (2) the clinical significance of dyadic processes in caregiving relationships between patients and care partners in the context of patient-caregiver-clinician encounters.||June 23, 2021.|
|NIH||NIH Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)||Up to USD $450,000 for up to 3 years.||This is pilot projects to evaluate the preliminary effectiveness of interventions targeting preschool attention deficit hyperactivity disorder (ADHD) symptoms and impairments. An emphasis is placed on studies that take a theory-driven, empirical approach to developing and testing interventions intended to impact current ADHD symptoms and impairments and/or prevent or forestall the emergence of co-occurring disorders or additional ADHD-related impairments.||July 1, 2021; March 1, 2022.|
|NIH||NIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)||--||This encourages investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.||July 1, 2021; October 20, 2021; February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024.|
|NIH||Research on Current Topics in Alzheimer's Disease and Its Related Dementias |
- PAR-19-070 (R01 Clinical Trial Optional)
- PAR-19-071 (R21 Clinical Trial Not Allowed)
|--||This invites applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of notices that are linked at the top of the funding opportunity websites.||July 9, 2021; November 12, 2021.|
|NIH||NIH Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)||--||This supports exploratory studies developing or using novel tools or technologies or testing novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. This promotes research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.||July 14, 2021; September 7, 2021; July 14, 2022; September 7, 2022.|
|NIH||NIH Tobacco Regulatory Science (R01 Clinical Trial Optional)||--||This supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).||July 14, 2021, February 15, 2022, July 14, 2022, February 14, 2023.|
|NIH||Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)||--||The intent of this funding is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies.||July 19, 2021; November 17, 2021; March 17, 2022; July 19, 2022; November 7, 2022|
|NIH||NIH Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)||--||The National Institute on Drug Abuse (NIDA) CEBRA fosters highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research.||August 10, 2021; March 8, 2022; August 10, 2022; March 8, 2023; August 10, 2023; March 8, 2024.|
|NIH||New Models of Integrated HIV/AIDS, Addiction, and Primary Care Service|
- PAR-20-273 (R01 Clinical Trial Required)
- PAR-20-274 (R34 - Clinical Trial Optional)
|--||This supports the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.|
- PAR-20-273 (R01 Clinical Trial Required): This seeks applications that will test comprehensive service delivery models. Applicants needing to develop, refine, and/or test key components of such a model are encouraged to apply to the companion R34.
- PAR-20-274 (R34 - Clinical Trial Optional): The R34 grant mechanism is intended to encourage planning research by providing support for the initial development of a clinical trial or research project.
|August 11, 2021; November 18, 2021; August 11, 2022; November 18, 2022; August 11, 2023|
|NIH||NIH Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)||--||The primary objective is to move Digital Therapeutics (DTx) to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.||Deadlines: September 8, 2021; January 10, 2022; September 8, 2022; January 10, 2023; September 8, 2023; January 10, 2024.|
|NIH||NIH High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed)||--||This will support high-throughput screening approaches to identify novel receptors, signal transducers, or small molecules that modulate Substance Use Disorder (SUD)-relevant signal transduction pathways (dopamine, opioid, cannabinoid, nicotinic, or other appropriately justified pathway). Applicants may also propose secondary screens and/or validation of high value identified targets.||September 15, 2021.|
|NIH||Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention|
- PA-18-861 (R03 - Clinical Trial Optional)
- PA-18-862 (R21 - Clinical Trial Optional)
- PA-18-863 (R01 - Clinical Trial Optional)
|--||The purpose is to encourage research grant applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination.||Standard dates apply until January 8, 2022 (R03), or September 8, 2021 (R21, R01).|
|NIH||Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2||--||This NOSI encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:|
- SARS-CoV-2 candidate vaccines
- non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
- therapeutic approaches to treat COVID-19
|Applications will be accepted once a month through September 14, 2021.|
|NIH||NIH Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD)||--||These support applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).|
RFA-AG-22-016 (R61/R33 Clinical Trial Required): Supports pilot research (R61) to identify, measure, and assess the malleability of psychological or interpersonal adherence-relevant targets that, if successful, can transition to an R33 phase for implementation of rigorous, proof-of-concept intervention studies. Deadline: September 15, 2021.
PAR-21-207 (R01 Clinical Trial Optional): Specifically supports ancillary studies to ongoing, early- to late-stage clinical intervention trials. Ancillary studies should provide the opportunity to explore novel psychological and interpersonal mechanisms by collecting new data from participants enrolled in the ongoing parent study. Deadlines: September 15, 2021; January 26, 2022.
|RFA-AG-22-016 (R61/R33 Clinical Trial Required): September 15, 2021.
PAR-21-207 (R01 Clinical Trial Optional): September 15, 2021; January 26, 2022.
|NIH||NIH Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches: Various Opportunities||--||This solicits applications for research projects that will advance translational research to better understand risk and resilience for suicide in the context of the NIMH Research Domain Criteria (RDoC) framework, specifically the Positive Valence Systems (PVS) domain, and lead to novel interventions. |
PAS-21-215 (R21 Clinical Trial Optional): For exploratory, smaller scope, highly-innovative projects. Deadline: October 16, 2021.
PAS-21-216 (R01 - Clinical Trial Optional): For projects that require more time, a more flexible budget, and are larger in scope. Deadline: October 5, 2021.
|PAS-21-215 (R21 Clinical Trial Optional): October 16, 2021.
PAS-21-216 (R01 - Clinical Trial Optional): October 5, 2021.
|NIH||NIH Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 - Clinical Trial Optional)||--||This will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of cardiovascular disease (CVD) in Type 1 Diabetes Mellitus (T1DM), and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM.||October 15, 2021.|
|NIH||NIH Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)||--||This is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinical trials and patient care. This initiative will support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative will leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples.||Deadlines: November 3, 2021.|
|NIH||NIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)||--||This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.||November 8, 2021; March 7, 2022; November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024.|
|NIH||Emotion Regulation, Aging and Mental Disorder|
- PA-19-094 (R01 Clinical Trial Not Allowed)
- PA-19-095 (R21 Clinical Trial Not Allowed)
|--||This encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Applicants with preliminary data may wish to apply using the R01 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies utilizing existing data may wish to apply using the R21 mechanism.||Standard dates apply until January 8, 2022.|
|NIH||Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)||--||This supports projects that utilize open-access data available via the Bioinformatics Resource Centers (BRCs), alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases. Projects focused on influenza, Mycobacterium tuberculosis (TB), antimicrobial resistance and malaria are encouraged although projects based on other pathogens relevant to National Institute of Allergy and Infectious Diseases will be supported.||Standard dates apply until January 8, 2022.|
|NIH||Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities||--||This seeks research strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US. Research is needed to understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), and herpes zoster) among adults in the US and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions.||This notice applies to receipt dates through January 8, 2022.|
|NIH||Bioengineering Research Grants (BRG)|
- PAR-19-158 (R01 Clinical Trial Not Allowed)
- PAR-19-159 (R01 Clincal Trial Required)
|--||The purpose is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice.||Standard dates apply until January 8, 2022.|
|NIH||Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed)||--||The purpose is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.||Standard dates apply until May 8, 2022.|
|NIH||NIH Dissemination and Implementation Research in Health||--||This supports innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.|
- PAR-19-274 (R01 Clinical Trial Optional)
- PAR-19-275 (R21 Clinical Trial Optional)
-PAR-19-276 (R03 Clinical Trial Not Allowed)
|Standard dates apply until May 8, 2022.|
|NIH||Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)||--||The purpose of this grant is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.||Applications will be accepted on a rolling basis, expiring on September 1, 2022.|
|NIH||Notice of Special Interest (NOSI): Research in the Emergency Setting||--||This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Please see opportunity details for the lists of NIH Institutes and Centers and associated funding opportunity announcements to use for submission of an application in response to this NOSI.||This notice applies to receipt dates through September 8, 2022.|
|NIH||Co-infection and Cancer|
- PAR-20-062 (R01 Clinical Trial Not Allowed)
- PAR-20-061 (R21 Clinical Trial Not Allowed)
|--||The purpose is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents - either concurrently or sequentially- and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.||Standard dates apply until January 8, 2023|
|NIH||Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)||--||This encourages projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. This is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.||Standard dates apply until January 8, 2023.|
|NIH||Notice of Special Interest (NOSI): Adopting Techniques and Tools Developed from the BRAIN Initiative Toward National Institute of Mental Health (NIMH) Strategic Research Priorities||--||NIMH is encouraging the submission of applications proposing to use the following types of tools/technologies developed in the BRAIN Initiative:|
- Technologies that enable causal in vivo behavioral neuroscience experimental designs to probe functions of neural circuits implicated in the above-mentioned behavioral domains
- Technologies that analyze and manipulate complex circuits with a goal to provide comprehensive circuit diagrams
- Technologies that monitor neural activity and in vivo behaviors
- Interventional tools
- Technologies that allow examination of developmental time course and/or sex differences in mental health-relevant circuit function
- Computational modeling approaches and data analysis
|This notice applies to receipt dates through May 8, 2023.|
|NIH||Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19 Pandemic||--||The purpose of this NOSI is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:|
- Encourage research to address the rehabilitation needs of survivors of COVID-19
- Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions
- Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities
|This notice applies to receipt dates through May 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)||--||This supports research that improves our understanding of the behavioral, social, and economic effects of the pandemic and to enhance our ability to control its spread. These effects will likely be particularly acute for NIH-designated health disparity populations , and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.||This notice applies to receipt dates May 8, 2023.|
|NIH||Occupational Safety and Health Research (R01) ||--||The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries.||Standard dates apply until November 18, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes||--||This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to:|
- Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an "accelerated aging" phenotype;
- Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes;
- Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors;
- Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints;
- Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and
- Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging.
|This notice applies to receipt dates through January 7, 2024.|
|NIH||NIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional) ||--||This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.||Standard AIDS dates apply until January 8, 2024.|
|NIH||NIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed) ||--||This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities.||Standard AIDS dates apply until January 8, 2024.|
|NIH||Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)||--||This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.||Standard dates apply until January 8, 2024.|
|NIH||Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders||--||National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.||This notice applies to receipt dates through January 8, 2024.|
|NIH||NIH Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes||--||National Institute of Mental Health (NIMH) seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden.|
PAR-21-211 (R34 Clinical Trial Required): This supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials.
PAR-21-210 (R01 Clinical Trial Required): This supports fully-powered, definitive effectiveness studies focused on post-acute phase interventions
|Standard dates apply until March 17, 2024.|
|NIH||Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis||--||This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease.||This notice applies to receipt dates through May 8, 2024.|
|NIH||NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Various Opportunities||Up to USD $50,000 per year for up to 2 years.|| PA-21-231 (R03 Basic Experimental Studies with Humans Required): This is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. |
PA-21-221 (R03 Clinical Trial Required): This supports clinical trials that fall within the NICHD mission.
|Standard dates apply until May 8, 2024.|
|NIH||NIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment||--||The purpose is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. Each partnership should include at least one academic and one industrial organization.|
PAR-21-166: R01 - Clinical Trial Not Allowed
PAR-21-206: R01 - Clinical Trial Optional
|Standard dates apply until May 8, 2024.|
|NIH||Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)||--||This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.||This notice applies to receipt dates through July 5, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19||--||National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.||This notice applies to due dates through September 7, 2024.|
|NIH||Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection||--||This NOSI encourages research to understand: |
- The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
- The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
- The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.
|This notice applies to due dates through September 8, 2024.|
|NIH||NIH Parent Announcements||--||NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)|
Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) (PA-20-184)
Research Project Grant (Parent R01 Clinical Trial Required) (PA-20-183)
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) (PA-20-200)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) (PA-20-195)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) (PA-20-194)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) (PA-20-196)
|Standard dates apply unless otherwise stated.|